Reuters logo
6 months ago
BRIEF-FDA accepts BLA for Mylan, Biocon's proposed biosimilar pegfilgrastim for review
February 16, 2017 / 1:21 PM / 6 months ago

BRIEF-FDA accepts BLA for Mylan, Biocon's proposed biosimilar pegfilgrastim for review

Feb 16 (Reuters) - Mylan NV :

* U.S. FDA accepts Biologics License Application (BLA) for Mylan and Biocon's proposed biosimilar pegfilgrastim for review

* Mylan NV says FDA goal date set under biosimilar user fee act (BSUFA) is Oct. 9, 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below